Investors

Market Opportunities

Hepatitis B Virus Global Statistics

Global Statistics
  • 2 Billion people have been infected (1 out of 3 people).
  • 240 Million people are chronically infected.
  • 10-30 Million will become infected each year.
  • Chronic HBV infection is the major cause of hepatocellular carcinoma
  • Over 500,000 people die each year from HBV and its complications

Global Market for HBV Drugs

HBV Drugs
  • HBV anti-viral drugs: $3.1 Billion will hit $4.4 Billion (2019)
  • Drugs do not cure chronic disease.
  • No FDA approved and marketed therapeutic vaccine.

Global Market for Vaccines

Vaccines
  • Human and animal vaccines: $25 Billion and projected to grow to $100 Billion (2024)
  • Hepatitis B virus vaccines: $1.0 Billion and projected to grow to 1.8 Billion (2018)
  • Therapeutic immunotherapy/vaccines; >$3 billion

Financing-to-Date

The Company has secured more than $3 million to fund its vaccine development and operations. Most of the financing has come from Connecticut Innovations ( www.ctinnovations.com), followed by G. P. Healthcare ( www.gerpanghealthcare.com), Shandong Province, China; and from non-dilutive funding sources such as grants and awards.